NCT01915108View on ClinicalTrials.gov

Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal

NACompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Respiratory Complication
Interventions
DRUG

Remifentanil

All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).

All Listed Sponsors
lead

Sangjin Park

OTHER

NCT01915108 - Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal | Biotech Hunter | Biotech Hunter